BRIEF

on Curiteva

Curiteva Surpasses 1,000 Procedures With Inspire(R) Cervical Trabecular PEEK(TM)

HUNTSVILLE, AL / ACCESSWIRE / June 4, 2024 / Curiteva, Inc., a privately held manufacturing and technology company, announces over 1,000 patients have been treated with the novel 3D printed Inspire Cervical Trabecular PEEK Interbody Fusion System, resulting in over 2,000 Inspire implants placed in patients. The Inspire Cervical System was introduced with a limited launch in April of 2023, followed by full commercialization in July.

"I am seeing CT scans of patients at their three-month follow-up showing bone bridging from endplate to endplate through the porous structure of the device. This is unprecedented in my 40 years of practice," commented Randy Dryer, MD, Curiteva's Medical Director. "Other companies have touted a porous PEEK implant, but the Curiteva Trabecular PEEK is forming bone across the entire implant."

The Inspire platform is manufactured with a proprietary, patented Fused Filament Fabrication 3D printer designed, programmed, and built by Curiteva. This additive process produces a fully interconnected porous structure to promote osseointegration, improve radiographic assessment, and deliver superior biomechanics. The combination of HAFUSE nanotechnology surface treatment and the porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation, and healing.

Chad Falciani, Founder and Chairman of the board for Curiteva, commented, "We're extremely proud of this milestone. Surpassing 1,000 procedures and over 2,000 implants within a year of commercialization is a testament to our team's effort and focus. Next month we will be expanding our Inspire Technology into lumbar, adding momentum to our growth in the quarters to come."

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Curiteva news